Category Archives: Other

Reviews that are lab-based (e.g. genes, pharmaceuticals) or on unique groups of people (e.g. fishermen, nurses)

Global burden of HIV among long-distance truck drivers: A systematic review and meta-analysis

2024

Objectives The purpose of this study was to systematically summarise the empirical evidence on the prevalence of HIV among long-distance truck drivers (LDTDs) from all parts of the world. Design...

Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations

2024

OBJECTIVE: Assessing the prevalence of resistance and drug resistance mutations (DRMs) in HIV/AIDS patients towards integrase strand transfer inhibitors (INSTIs), particularly the 2nd-generation INSTIs, provides evidence for rational clinical drug...

Using mHealth technologies for case finding in tuberculosis and other infectious diseases in Africa: Systematic review

2024

BACKGROUND: Mobile health (mHealth) technologies are increasingly used in contact tracing and case finding, enhancing and replacing traditional methods for managing infectious diseases such as Ebola, tuberculosis, COVID-19, and HIV....

Occupational post-exposure prophylaxis among healthcare workers: A scoping review of factors affecting optimal utilization

2024

INTRODUCTION: Post-exposure prophylaxis (PEP) is an efficacious prevention method when initiated promptly after an HIV exposure. Yet, PEP has been underutilized, even among healthcare workers (HCWs) with occupational exposure in...

Caregiver-assisted testing with HIV self-test kits for children 18 months and older: A GRADE systematic review

2024

Caregiver-assisted testing using HIV self-test (CG-HIVST) kits has been proposed to enhance paediatric HIV case finding and contribute toward ending paediatric HIV/AIDS by 2030. We conducted a systematic review to...

Global and regional genetic diversity of HIV-1 in 2010-21: Systematic review and analysis of prevalence

2024

Background The extensive global genetic diversity of HIV-1 poses a major challenge to HIV vaccine development. We aimed to determine recent estimates of and changes in the global and regional...

Analysis of drug-drug interactions in patients with HIV and metabolic syndrome

2024

BACKGROUND: People with HIV (PWH) are living longer directly related to benefits of highly effective antiretroviral therapy (ART). However, concurrent with improved longevity is the growing prevalence of metabolic comorbidities...

Delving deeper into the mechanisms fundamental to HIV-associated immunopathology using single-cell sequencing techniques: A scoping review of current literature

2024

Human immunodeficiency virus (HIV) infection has evolved into an established global pandemic over the past four decades; however, despite massive research investment globally, the precise underlying mechanisms which are fundamental...

Efficacy and tollerability of INI-based 2-drug regimen in virosuppressed persons living with HIV: A systematic review and meta-analysis

2024

BACKGROUND: The aim of this meta-analysis was to synthesize the available evidence from the literature on the efficacy and safety of integrase inhibitor-based two drug regimens compared to triple drug...

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence

2024

BACKGROUND AND AIM: Human immunodeficiency virus (HIV) remains a significant global health challenge, with approximately 39 million people living with HIV worldwide as of 2022. Despite progress in antiretroviral therapy,...

Population pharmacokinetic simulations for dose optimization of tenofovir disoproxil fumarate in HIV-infected patients with moderate-to-severe renal impairment

2024

Tenofovir disoproxil fumarate (TDF) requires dosage adjustments from the standard 300 mg once daily to every 48–96 h for moderate-to-severe renal impairment to avoid excessive exposure. However, this extended interval...

Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir

2024

INTRODUCTION: Lenacapavir is the first HIV-1 capsid inhibitor administered subcutaneously twice yearly. While lenacapavir is currently only indicated as salvage therapy, it has the potential to become a foundation of...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!